


INFORMATION DISCLOSURE CITATION FORM PTO-1449 (Modified) (Use several sheets if necessary)	ATTY. DOCKET NO. 4099-0002.31	SERIAL NO. 09/660,468
	APPLICANT Lau and Wan	
	FILING DATE September 12, 2000	GROUP 1646 / 647



## U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
PR	*	4,683,199	07/28/87	Palladino			
	*	4,791,101	12/13/88	Adolf			
	*	5,098,702	03/24/92	Zimmerman, et al.			
	*	5,141,735	08/25/92	Bellemin et al.			
	*	5,248,499	08/28/93	Czarniecki et al.			
	*	5,624,895	04/29/97	Sobel			
	*	5,698,194	12/16/97	Hadden			
	*	5,720,952	02/24/98	Clark et al.			
	*	5,843,423	12/01/98	Lyman et al.			
	*	5,871,725	02/16/99	Schwarz			
	*	5,895,646	04/20/99	Wang			
	*	5,910,303	06/08/99	Takayama et al.			
	*	5,919,443	07/06/99	Michaelis et al.			
	*	6,117,423	09/12/00	Berg			
PR	*	6,165,459	12/26/00	Broxmeyer et al.			


## FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	Chirigos, M.A., et al., "Leukocyte interleukin, inj. (LI) augmentation of natural killer cells and cytolytic t-lymphocytes" <i>Immunopharmacology and Immunotoxicology</i> 17(2):247-264 (1995).
	Pulley, M.S., et al., "Intravenous, Intralesional and Endolymphatic Administration of Lymphokines in Human Cancer" <i>Lymphokine Research</i> 5(supp. 1):S157-S163 (1986).
	Stark, G.R., "Genetic analysis of interferon and other mammalian

David R. 8/24/2

signaling pathways" The Harvey Lectures Series 93:1 16 (1999).	
	
EXAMINER	DATE CONSIDERED
<i>Donald Rames</i>	<i>8/24/2</i>
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPE 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

**RECEIVED**  
MAR 05 2001

REC. CENTER 1600/2300